Professor Jin Li & Professor Joon Oh Park: Carrying the Torch Forward with Unity and Collaboration — FACO as a Platform for Advancing Comprehensive Academic Cooperation and the Joint Progress of Asian Clinical Oncology
Editor’s Note: The 13th Federation of Asian Clinical Oncology (FACO) Annual Meeting was grandly held in Shanghai on October 24–25, 2025. As a collaborative organization jointly initiated by the…
Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…
ESMO China Voice | Professor Jiesong Wang: The iPET-NCCN-IPI Model May Optimize Risk Stratification in Diffuse Large B-Cell Lymphoma
Editor’s Note: The 2025 European Society for Medical Oncology (ESMO) Annual Congress was grandly held in Berlin, marking another milestone in global oncology research. In the field of hematologic malignancies,…
ESMO China Voice | Dr. Cong Sun: Grade 3B Follicular Lymphoma Is an Independent Risk Factor Affecting Both PFS and OS
Editor’s Note: The 2025 European Society for Medical Oncology (ESMO) Annual Congress was grandly held in Berlin, marking another wave of major scientific breakthroughs in oncology. In the field of…
13th FACO Annual Academic Conference Grandly Held in Shanghai! Leading Experts from China, Japan, and South Korea Gather to Foster Clinical Oncology
Editor’s Note: Promoting collaboration through exchange, and seeking mutual success through cooperation — on October 24, 2025, the 13th Federation of Asian Clinical Oncology (FACO) Annual Conference was grandly held…
Professor Li Jin: Asian Clinical Oncology Experts Converge at FACO Conference to Jointly Promote Regional Collaboration and Advance the Level of Diagnosis and Treatment for Common Asian Cancers
The 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025) will be grandly held in Shanghai from October 24 to 25, 2025. The conference is jointly organized by the Federation of Asian Clinical Oncology (FACO), the Chinese Society of Clinical Oncology (CSCO), the Beijing CSCO Clinical Oncology Research Foundation, and the Eastern Clinical Oncology Research Center (ECCO). The theme is "Asian Clinical Oncology – Cooperation and Innovation," aiming to promote collaboration in drug research and new drug development, combine surgical and/or radiotherapy methods to jointly explore more efficient treatment options, and enhance the overall standards and effectiveness of cancer treatment.
ESMO Interview | Dr. Bryan Li: From Bladder Removal to Bladder Preservation, Perioperative Immunotherapy Reshapes MIBC Treatment
Editor's Note: Immunotherapy has rapidly developed in recent years, achieving remarkable clinical results in the treatment of advanced bladder cancer. With the continued advancement of clinical research, the application of…
CSCO 2025 | Professor Wei Li: PARP Inhibitors Transform Early BRCA-Mutated Breast Cancer — Precision and Combination Strategies Drive Progress
Editor’s Note: Patients carrying BRCA gene mutations face a significantly increased risk of developing breast cancer, and conventional therapies often yield suboptimal results. PARP inhibitors, by leveraging the mechanism of…
CSCO 2025 | Professor Guohong Song: Immunotherapy Redefines Triple-Negative Breast Cancer Through Precision and Intensified Treatment
Editor’s Note: In recent years, immunotherapy, particularly PD-1/PD-L1 inhibitors, has profoundly transformed the treatment paradigm for triple-negative breast cancer (TNBC). The KEYNOTE-522 trial demonstrated that neoadjuvant immunotherapy combined with chemotherapy…